At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Analgesics
- Mechanism of Action Neurokinin 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
Most Recent Events
- 26 Feb 2001 Profile reviewed but no significant changes made
- 24 Jan 1995 No-Development-Reported for Pain in United Kingdom (Unknown route)